Vaxxas Secures U.S. Patent for Needle-Free Vaccine Manufacturing Technology
Wednesday, March 19, 2025
Vaxxas has obtained a new patent from the United States Patent Office for its proprietary manufacturing technology.
The high-density microarray patch (HD-MAP) features thousands of tiny projections that carry a dried vaccine formulation. When applied to the skin, the patch delivers the vaccine directly to immune cells below the surface.
HD-MAP technology offers several advantages over traditional needle-based vaccinations. The dried vaccine formulation has shown increased stability at higher temperatures in early clinical studies, potentially reducing the need for cold-chain storage.
Clinical research has also demonstrated the safety and effectiveness of the HD-MAP, indicating its ability to produce immune responses comparable to or greater than those generated by injections, even at lower doses.
Designed for ease of administration, the HD-MAP system could play a key role in future pandemic responses by providing an efficient and accessible alternative to conventional vaccination methods.
This development strengthens the company’s intellectual property rights for its high-density microarray patch (HD-MAP), a novel needle-free vaccine delivery platform.
The HD-MAP consists of thousands of microscopic projections designed to deliver vaccines by penetrating the skin. The newly patented printhead system ensures precise and consistent application of a dried vaccine formulation onto the microprojections in small doses. When applied to the skin, the patch efficiently delivers the vaccine to immune cells beneath the surface.
This method enables high-speed, large-scale production while maintaining the quality of the final product.
The new U.S. patent expands Vaxxas’ global intellectual property portfolio, which now includes 43 issued patents. It strengthens the company’s exclusive rights to manufacture and commercialise its technology across the United States, Europe, Asia, and Australia.
Vaxxas aims to improve vaccine performance while addressing the economic and logistical challenges of traditional needle-and-syringe vaccination.
Source: businesswire.com
